Download PDF
Endoscopy 2012; 44(07): 707-710
DOI: 10.1055/s-0032-1309903
Case report/series
© Georg Thieme Verlag KG Stuttgart · New York

Endoscopic ablation of Barrett’s neoplasia with a new focal radiofrequency device: initial experience with the Halo60

B. Allen
1   Centre for Liver Disease and Digestive Disorders, The Royal Infirmary of Edinburgh, Edinburgh, UK
,
N. Kapoor
2   Gastrointestinal Unit, Royal Liverpool University Hospital, Liverpool, UK
,
R. Willert
3   Department of Gastroenterology, Central Manchester University Hospitals NHS Trust, Manchester, UK
,
H. McEwan
4   Upper Gastrointestinal Surgical Unit, Glasgow Royal Infirmary, Glasgow, UK
,
G. Fullarton
4   Upper Gastrointestinal Surgical Unit, Glasgow Royal Infirmary, Glasgow, UK
,
I. Penman
1   Centre for Liver Disease and Digestive Disorders, The Royal Infirmary of Edinburgh, Edinburgh, UK
› Author Affiliations
Further Information

Publication History

submitted 05 March 2012

accepted after revision 27 April 2012

Publication Date:
21 June 2012 (online)

Also available at
    Permissions and Reprints

Radiofrequency ablation (RFA) is an accepted treatment for the eradication of dysplastic Barrett’s esophagus (DBE) and residual Barrett’s esophagus after endoscopic resection of intramucosal adenocarcinoma. Circumferential balloon-based and focal catheter-based RFA devices are currently used (the Halo360 and Halo90). However, a new smaller focal ablation device (the Halo60) has been developed, which may be of benefit in patients with short tongues of Barrett’s neoplasia, small residual islands, difficult anatomy, or strictures. We report the first use of this device in 17 patients with either DBE or residual Barrett’s esophagus after endoscopic resection of intramucosal adenocarcinoma.

 

  • References

  • 1 Shaheen NJ, Sharma P, Overholt BF et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. NEJM 2009; 360: 2277-2288
    CrossrefPubMedGoogle Scholar
  • 2 American Gastroenterological Association. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology 2011; 140: 1084-1091
    CrossrefPubMedGoogle Scholar
  • 3 Sharma VK, Wang KK, Overholt BF et al. Balloon-based circumferential endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients (with video). Gastrointest Endosc 2007; 65: 185-195
    CrossrefPubMedGoogle Scholar
  • 4 Wani S, Sayana H, Sharma P. Endoscopic eradication of Barrett’s esophagus. Gastrointest Endosc 2010; 71: 147-166
    CrossrefPubMedGoogle Scholar
  • 5 Wani S, Puli SJ, Shaheen NJ et al. Esophageal adenocarcinoma in Barrett’s esophagus after endoscopic ablative therapy: A meta-analysis and systematic review. Am J Gastroenterol 2009; 104: 502-513
    CrossrefPubMedGoogle Scholar
  • 6 Shaheen NJ, Peery AF, Overholt BF et al. Biopsy depth after radiofrequency ablation of dysplastic Barrett’s esophagus. Gastrointest Endosc 2010; 72: 490-496e1
    CrossrefPubMedGoogle Scholar
  • 7 Shaheen NJ, Overholt BF, Sampliner RE et al. Durability of radiofrequency ablation of Barrett’s esophagus with dysplasia. Gastroenterology 2011; 141: 460-468
    CrossrefPubMedGoogle Scholar
  • 8 Pouw RE, Wirths K, Eisendrath P et al. Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett’s esophagus with early neoplasia. Clin Gastroenterol Hepatol 2010; 8: 23-29
    CrossrefPubMedGoogle Scholar
  • 9 Fleischer DE, Overholt BF, Sharma VK et al. Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc 2008; 68: 867-876
    CrossrefPubMedGoogle Scholar